Logan Capital Management Inc. Has $24.85 Million Stake in Eli Lilly and Company (NYSE:LLY)

Logan Capital Management Inc. reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,194 shares of the company’s stock after selling 125 shares during the quarter. Eli Lilly and Company accounts for about 1.0% of Logan Capital Management Inc.’s holdings, making the stock its 21st biggest position. Logan Capital Management Inc.’s holdings in Eli Lilly and Company were worth $24,854,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Laraway Financial Advisors Inc boosted its stake in Eli Lilly and Company by 316.7% during the 4th quarter. Laraway Financial Advisors Inc now owns 11,969 shares of the company’s stock valued at $9,240,000 after purchasing an additional 9,097 shares during the last quarter. LifePlan Investment Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 4.6% in the fourth quarter. LifePlan Investment Advisors Inc. now owns 318 shares of the company’s stock valued at $246,000 after acquiring an additional 14 shares in the last quarter. Lionshead Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $453,000. Integral Health Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 280.0% in the 4th quarter. Integral Health Asset Management LLC now owns 38,000 shares of the company’s stock worth $29,336,000 after buying an additional 28,000 shares during the last quarter. Finally, Investor s Fiduciary Advisor Network LLC purchased a new stake in Eli Lilly and Company during the fourth quarter worth about $2,482,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE LLY opened at $736.21 on Monday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a market capitalization of $697.73 billion, a price-to-earnings ratio of 62.87, a PEG ratio of 1.40 and a beta of 0.48. The stock has a 50-day moving average of $810.98 and a 200 day moving average of $810.32. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.58 earnings per share. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.13% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

LLY has been the subject of several research reports. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. UBS Group dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research note on Friday, January 17th. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 target price on the stock. Finally, Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,002.80.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.